Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IMDRF Tackles Confusion Over Clinical Evidence Expectations for Device Software

This article was originally published in SRA

Executive Summary

If all goes to plan, the International Medical Device Regulators Forum will have completed by July a draft guidance that explores when and to what level clinical evaluation and evidence is necessary or acceptable to support marketing authorizations of software as a medical device (SaMD)1.

You may also be interested in...



Saudi FDA Consults On Regulating Device Software, Distribution Requirements

Saudi Arabia has proposed adopting IMDRF guidelines on the regulation of medical device software. It has also issued a separate proposal to help medical device establishments comply with national regulatory requirements on the storage, handling and distribution of medtech products.

Next Step In Global Convergence: FDA Looks To Make IMDRF Software Guidance Its Own

The US agency issued a draft guidance on clinical evaluation considerations for "software as a medical device." But FDA did not write the guidance internally. Instead it is an International Medical Device Regulators Forum document that was put together collaboratively by regulatory officials from across the globe. This is the first time FDA is attempting to wholesale adopt an IMDRF guidance document as its own.

New EU Approvals

The Pink Sheet’s list of EU centralized approvals of new active substances has been updated with seven new products including Roche's Polivy for treating diffuse large B-cell lymphoma. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).

UsernamePublicRestriction

Register

MT040739

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel